Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Glasmacinal - EpiEndo Pharmaceuticals

Next Previous
Drug Profile

Glasmacinal - EpiEndo Pharmaceuticals

Alternative Names: EP-395

Latest Information Update: 13 Mar 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator EpiEndo Pharmaceuticals
  • Class Anti-inflammatories; Macrolides
  • Mechanism of Action Epithelial cell modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Chronic obstructive pulmonary disease

Most Recent Events

  • 20 Feb 2025 EpiEndo Pharmaceuticals initiates enrolment in a phase-I trial (In volunteers) in Germany (PO) (NCT06677918),
  • 08 Nov 2024 EpiEndo Pharmaceuticals plans a phase I trial (In volunteers) in Germany (PO, Capsule) (NCT06677918) (EUCT2024-516187-29-00)
  • 07 Sep 2024 Pharmacodynamics data from a preclinical trial in Chronic obstructive pulmonary disease presented at the 34th Annual Congress of the European Respiratory Society Session (ESR-2024)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top